The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity.


Journal

EMBO reports
ISSN: 1469-3178
Titre abrégé: EMBO Rep
Pays: England
ID NLM: 100963049

Informations de publication

Date de publication:
03 02 2021
Historique:
received: 23 06 2020
revised: 02 12 2020
accepted: 03 12 2020
pubmed: 5 1 2021
medline: 1 6 2021
entrez: 4 1 2021
Statut: ppublish

Résumé

Although iron is required for cell proliferation, iron-dependent programmed cell death serves as a critical barrier to tumor growth and metastasis. Emerging evidence suggests that iron-mediated lipid oxidation also facilitates immune eradication of cancer. However, the regulatory mechanisms of iron metabolism in cancer remain unclear. Here we identify OTUD1 as the deubiquitinase of iron-responsive element-binding protein 2 (IREB2), selectively reduced in colorectal cancer. Clinically, downregulation of OTUD1 is highly correlated with poor outcome of cancer. Mechanistically, OTUD1 promotes transferrin receptor protein 1 (TFRC)-mediated iron transportation through deubiquitinating and stabilizing IREB2, leading to increased ROS generation and ferroptosis. Moreover, the presence of OTUD1 promotes the release of damage-associated molecular patterns (DAMPs), which in turn recruits the leukocytes and strengthens host immune response. Reciprocally, depletion of OTUD1 limits tumor-reactive T-cell accumulation and exacerbates colon cancer progression. Our data demonstrate that OTUD1 plays a stimulatory role in iron transportation and highlight the importance of OTUD1-IREB2-TFRC signaling axis in host antitumor immunity.

Identifiants

pubmed: 33393230
doi: 10.15252/embr.202051162
pmc: PMC7857436
doi:

Substances chimiques

Antigens, CD 0
CD71 antigen 0
Receptors, Transferrin 0
Iron E1UOL152H7
OTUD1 protein, human EC 3.4.19.12
Ubiquitin-Specific Proteases EC 3.4.19.12
IREB2 protein, human EC 4.2.1.3
Iron Regulatory Protein 2 EC 4.2.1.3

Banques de données

GEO
['GSE140059']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e51162

Informations de copyright

© 2021 The Authors.

Références

Biochim Biophys Acta. 2006 Jul;1763(7):668-89
pubmed: 16872694
Nat Med. 2012 Aug;18(8):1224-31
pubmed: 22820642
Cell Res. 2020 Feb;30(2):146-162
pubmed: 31949285
J Biol Chem. 1994 Dec 9;269(49):30904-10
pubmed: 7983023
Br J Cancer. 2014 Jul 29;111(3):551-8
pubmed: 24937664
Cancer. 2001 Jun 15;91(12):2214-21
pubmed: 11413508
Semin Oncol. 2006 Feb;33(1):74-85
pubmed: 16473646
Science. 2009 Oct 30;326(5953):722-6
pubmed: 19762597
J Vis Exp. 2012 Sep 11;(67):
pubmed: 22990604
Clin Chim Acta. 2020 May;504:180-189
pubmed: 31790701
Nanomedicine (Lond). 2015 Oct;10(19):3003-3013
pubmed: 26420013
Am J Respir Cell Mol Biol. 2020 May;62(5):554-562
pubmed: 32017592
Curr Pharm Biotechnol. 2014;15(12):1125-40
pubmed: 25496094
Nature. 2013 Apr 25;496(7446):518-22
pubmed: 23467095
Nature. 2017 Nov 30;551(7682):585-589
pubmed: 29143823
EMBO Rep. 2021 Feb 3;22(2):e51162
pubmed: 33393230
Nature. 2020 Sep;585(7823):113-118
pubmed: 32814895
Annu Rev Nutr. 2018 Aug 21;38:97-125
pubmed: 30130469
Fibrogenesis Tissue Repair. 2010 Jul 23;3:12
pubmed: 20653943
Science. 2019 Mar 29;363(6434):
pubmed: 30923193
Adv Exp Med Biol. 2019;1173:21-32
pubmed: 31456203
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Nature. 2019 May;569(7755):270-274
pubmed: 31043744
IUBMB Life. 2017 Jun;69(6):414-422
pubmed: 28349628
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
Nat Rev Cancer. 2019 Jul;19(7):405-414
pubmed: 31101865
Nature. 2016 Sep 22;537(7621):539-543
pubmed: 27626381
Cancer Cell. 2019 Jun 10;35(6):830-849
pubmed: 31105042
Nature. 2020 Mar;579(7799):415-420
pubmed: 32188940
Mol Cell Biol. 2009 Apr;29(8):2219-29
pubmed: 19223469
Science. 2009 Oct 30;326(5953):718-21
pubmed: 19762596
Nat Commun. 2017 Dec 13;8(1):2116
pubmed: 29235476
Science. 2020 Apr 3;368(6486):85-89
pubmed: 32241947
Nat Immunol. 2020 Mar;21(3):287-297
pubmed: 31932812
Nat Chem Biol. 2006 Aug;2(8):406-14
pubmed: 16850017
J Autoimmun. 2018 Nov;94:156-165
pubmed: 30100102
Wien Klin Wochenschr. 2015 Dec;127(23-24):907-19
pubmed: 26373748

Auteurs

Jia Song (J)

Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Tongtong Liu (T)

Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Yue Yin (Y)

Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Wei Zhao (W)

Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.

Zhiqiang Lin (Z)

Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Yuxin Yin (Y)

Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Dan Lu (D)

Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Fuping You (F)

Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH